Researchers at Baylor College of Medicine/Texas Children's Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial evaluating the safety, ...

HOUSTON--(BUSINESS WIRE)--Kuur Therapeutics today announced the launch of its new business in partnership with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Houston-based ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) Patent ...

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors. Now ...

CAR T-cells are becoming somewhat of a household name, but a new phase I trial is, for the first time, using CAR 'NKT' cells, featuring genetic modification of a different immune cell, natural killer ...

Please provide your email address to receive an email when new articles are posted on . A modified natural killer T-cell therapy expressing a chimeric antigen receptor and interleukin-15 appeared ...

HOUSTON--(BUSINESS WIRE)--Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of hematological and solid malignancies, today announced the ...

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades. The most ...

Pancreatic cancer is among the deadliest forms of cancer, with most patients diagnosed after the disease has already spread throughout the body. The five-year survival rate for metastatic cases hovers ...

Researchers at Baylor College of Medicine/Texas Children's Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial evaluating the safety, ...